This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Crikey.

Good last few days ! I now only need them to double to get my money back !!

I've averaged down neil as I think there is something behind the aggresive buying.. good luck.

Buy before the share price rockets..

Mitzy, your advice has always been well informed in the past. Do you know of any significant developments that you can share?
tau

Hi tau
Its the annual DNA conference in March and MMG in the past have issued a rns advising progress.

A complete disaster BEST is out and I have sold out at a big loss...

Oh dear.

Sorry top hear that mizi, and others.

Sorry to hear this news!

Click HERE

This is so typical of a dodgy company...long term sick leave receiving fat-cat salary for doing f-off work.


Boardroom drama hits Medical Marketing - Thursday, February 21, 2008, 01:57 PM

Medical Marketing International ( AIM: MMG ) plunged 40% today after the Company announced a board room shake-up.

The drug development Company said that Phil Cartmell had been appointed to the board of directors as Non-executive Chairman with immediate effect, replacing David Best who jointly co-founded Medical Marketing with Margaret Mitchell.

In a statement to the market, Medical Marketing added that Mr. Cartmell had the support of its major institutional shareholders, and that the Company was attempting to settle a disagreement between the co-founders and other stakeholders. David Best will still retain the title of Group Managing Director, and Margaret Mitchell is still IT Director, but in the update the Company confirmed that both individuals are on "long-term sick leave".

Medical Marketing also added that it had commissioned an independent review of the commercial potential of its three main technologies.

Phil Cartmell, Non-executive Chairman of MMI, commented:

"I am very pleased to be joining MMI at an important stage in its development. Whilst recognising the challenges presently facing the Board, the Company has a number of highly interesting projects in its pipeline which have been confirmed by the recent independent review to be of significant commercial potential."

Retail investors expressed disbelief after reading the update.

Lets see what Mike Walters has to say tonite.

Hi Mitzy, I'm not sure anyone saw this coming. I hope some positive news emerges from the independent commission for remaining holders. Still potential in the pipeline but it is not a steady ship by any means. Good luck to all.

Long-term sick leave - Eh? . . . . . . Does this translate into 'sacked', without sacking? This used to be called "Gardening Leave" by which an individual was salaried, yet unable to influence the running of the company.
+Dunno.
The ann. is not helping the sp. If the company needs cash, then having destroyed their sp is hardly a good starting point, other than it "might" mean institutional investors can snap-up the company on the cheap.
+Dunno - time as always, may bring some light.
This stock dropped 50% today - grief and that was after a considerable falter over recent weeks.

I am still in a state of shock I never saw this coming and just before the Dna conference in 10 days time ..I am fairly angry as David Best said several times that a deal was just around the corner now it seems it was a mickey finn.
Will I buy back in maybe at 6p.

A downgrade from buy to hold well its no surprise after yesterday.

David Best is a liar.

He certainly fooled a lot of people me included.

If the pipeline of products is still good and potentially commercial then this could be a buying opportunity? Would MMG become a takeover target?

Hi Andy, fundamentally the pipeline remains as it has been; with potential and a strong case for big pharma interest should trials prove positive. As you point out we have seen only a fornight ago with CEN that a tumbling share price combined with innovative products could lead to buyout interest. My concern with this co. at the moment is the position with Best and the fact that his personal situation was almost unknown despite the fact that it was a clearly price sensitive issue. He has been at the forefront of investor relations yet things seem to have boken down and the company is experiencing internal issues close to mutiny. Still, pipeline remains intact...as far as we know. Dr Stephenson is still on board...as far as we know and as long as there is enough cash MMI may actually produce the goods; in which case a buyout would obviousy be at a rate far higher than today. Despite the fact that this has always been an extremely speculative share, the price has held up reasonably over the past 18 months on hope alone suggesting that this may well be a buying opp...?